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Hypercholesterolemia
Gene therapyHypercholesterolemia is amedical condition often characterized by high levels of low-density lipoprotein cholester-
ol (LDL-C) in the blood. Despite the available therapies, not all patients show sufﬁcient responses, especially those
with very high levels of LDL-C or those with familial hypercholesterolemia. Regulation of plasma cholesterol levels
is very complex and several proteins are involved (both receptors and enzymes). From these, the proprotein
convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising pharmacologic target.
The objective of thiswork is to develop a new approach to inactivate PCSK9 by splice-switching oligonucleotides
(SSOs), converting the normal splice form to a natural, less abundant and inactive, splice variant.
For this purpose, a new RNA therapeutic approach for hypercholesterolemia based on SSOs was developed for
modulation of the splice pattern of human PCSK9 pre-mRNA. Our results show an increase of the selected splice
form at both the mRNA and protein level when compared to non-treated Huh7 and HepG2 cell lines, with
concomitant increase of the protein level of the low-density lipoprotein receptor (LDLR) demonstrating the spec-
iﬁcity and efﬁciency of the system. In vivo, full conversion to the splice form was achieved in a reporter system
when mice were treated with the speciﬁc oligonucleotide, thus further indicating the therapeutic potential of
the approach.
In conclusion, PCSK9 activity can be modulated by splice-switching through an RNA therapeutic approach. The
tuning of the natural active to non-active isoforms represents a physiological way of regulating the cholesterol
metabolism, by controlling the amount of LDL receptor available and the rate of LDL-cholesterol clearance.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).interspaced short palindromic
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Often characterized by high levels of low-density lipoprotein choles-
terol (LDL-C) in plasma, hypercholesterolemia [1] is one of the major
risk factors for the development of atherosclerosis [2] and cardiovascular
disease, principal causes of death in developed countries. Statins, a class
of cholesterol lowering drugs [3], are the established therapy for lowering
LDL-C levels in patients but, although considered efﬁcient and safe, all of
them present some limitation at higher doses [4]. Moreover, statins do
not sufﬁciently reduce LDL-C in high-risk or very high-risk subjects [5],
and frequently add-on therapies are required [4].
Several genes and their coded proteins controlling cholesterol me-
tabolism have been studied in order to identify additional pharmaceuti-
cal targets. One of the most promising is the proprotein convertase
subtilisin/kexin type 9 (PCSK9). PCSK9 was discovered in 2003 [6] and
identiﬁed as the third locus associated to autosomal dominant hyper-
cholesterolemia [7]. In 2005, a study from K.Maxwell et al. demonstrat-
ed that overexpression of PCSK9 mediated by an adenoviral vector
accelerates the degradation of the low-density lipoprotein receptorthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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protein responsible for the clearance of the LDL-C from plasma. Since
then, several other studies have shown the relation between gain [9]
and loss [9–11] of function mutations in PCSK9with the corresponding
increase and decrease of LDL-C levels in the blood, respectively.
PCSK9 is a natural post-transcriptional inhibitor of LDLR. It binds
with high afﬁnity to the LDLR (by the pro-segment/catalytic portion)
and induces its internalization and/or degradation in lysosomes [12]
through extra and intra [13] cellular pathways, regulating the amount
of LDLR at the membrane level. PCSK9 acts like a chaperone protein
and its function is independent of its catalytic activity [5]. Decreasing
the membrane LDLR levels promote the increase of LDL-C in the
blood. Like other genes involved in the metabolism of cholesterol,
PCSK9 is regulated by the transcription factors sterol-regulatory ele-
ment binding proteins (SREBPs) and thus is dependent on the amount
of sterols in the cell [14]. The levels of PCSK9 are inversely related with
the amount of cellular sterols, increasingwhen depleted and decreasing
when accumulated [14].
PCSK9 is mainly expressed in liver, small intestine, kidney and cen-
tral nervous system [6] and mediates the degradation of LDLR not only
in hepatocytes, but also in ﬁbroblasts and macrophages, but not in kid-
ney or adrenals [15]. Regarding other biological functions, genome-
wide expression analysis studies predict that PCSK9 could be involved
in the down-regulation of stress-response genes and speciﬁc inﬂamma-
tory cytokine pathways [16,17]. Additionally, an in vitro study shows
that PCSK9 can reduce the levels of the epithelium sodium channel
and so modulate the epithelial sodium absorption, thereby PCSK9 may
have a role controlling blood pressure [18].
Therapies to decrease the expression of the PCSK9 protein through
down-regulation of its mRNA by antisense oligonucleotides [19–22] or
small interfering RNA (siRNA) [23,24]; or inhibit its ability to bind to
the LDLR, mediated by antibodies [25,26]; or by disruption of the gene
by introduction of loss of function mutations by a clustered regularly
interspaced short palindromic repeats (CRISPR)/CRISPR-associated sys-
tem [27] have been developed in the last years with variable outcomes
[5,28].
In 2008, Schmidt et al. [29] described the existence of a PCSK9 splice
isoform (PCSK9sv), which is expressed in multiple tissues, but contrary
to full-length PCSK9 (PCSK9ﬂ), does not show activity in controlling cel-
lular levels of LDLRprotein. PCSK9sv differs fromPCSK9ﬂ by an in-frame
deletion of exon 8, preventing autocatalytic cleavage of the pro-domain
and the secretion of the protein [29].When comparedwith the full tran-
script, this splice form corresponds only to 18%. In vitro and in vivo stud-
ies (in HepG2 cells, human immortalized lymphoblasts and livers from
African greenmonkeys) show that sterol depletion suppresses the rela-
tive amount of the alternatively spliced transcript, while addition of
LDL-cholesterol conversely augments this fraction [30]. In the same
study, the half-life of the two transcripts was investigated, showing
that the full-length PCSK9 transcript has a signiﬁcantly reduced half-
life after sterol depletion, while there was no change in mRNA stability
of its alternatively spliced variant.
The ﬁnding of a human, natural, non-functional splice form opens a
new perspective for targeting intracellular PCSK9 in a more physiologi-
calmanner. Herewe demonstrate that it is possible tomodulate the two
PCSK9 splice forms by splice-switching oligonucleotides (SSOs) in two
human hepatocyte cell lines, Huh7 andHepG2, and in an in vivo context,
suggesting that this represents a promising approach for the develop-
ment of novel therapeutics.
2. Materials and Methods
2.1. Oligonucleotide design
Weused a combination of three predictive bioinformatics programs:
ESE3 (ESEﬁnder v3.0) [31,32], PESX and RESCUE-ESEWeb Server (v1.0)
[33,34] to predict target-accessibility in order to design a rational seriesof SSOs, each individually targeting exon 8 of the human PCSK9 gene
(GenBank accession no. NM_174936.3). Each oligonucleotide sequence
was BLASTed against all human sequences deposited in GenBank® da-
tabases. SSOs were synthesized as fully modiﬁed RNA 2′-O-methyl-
phosphorothioate oligonucleotides and RP-HPLC puriﬁed by DNA
Technology A/S (Denmark). After being dissolved in nuclease-free
water, the concentration of SSOs was assessed using a NanoDrop
(Thermo Scientiﬁc) and stored as frozen aliquots at−20 °C.
The commercially available siRNA used in this study is speciﬁc for
human PCSK9 (SASI_Hs01_00154292, SIGMA).
2.2. Oligonucleotide transfections
Hepatic HuH7 and HepG2 cells were maintained and cultivated in
Dulbecco's Modiﬁed Eagle's medium plus 10% FBS at 37 °C, 5% CO2
and 95% humidity. The cells were seeded at a density of 104 (Huh7)
and 1.4 × 105 (HepG2) cells per well in a 24-well plate the day before
transfection, in order to be approximately 80% conﬂuent the next day.
Transfection of the SSO constructs and the siRNA was performed with
Lipofectamine® 2000 (Life Technologies) or Lipofectamine® RNAiMax
(Life Technologies), respectively, and according to the manufacturer's
protocols. The transfection complexes were left in the culture for 24 h,
after which medium was changed or cells were harvested.
2.3. Sterol starvation by LPDS incubation
Hepatic Huh7were seeded at a density of 3 × 104 cells perwell in a 6
well plate the day before transfection in order to be approximately 50–
60% conﬂuent the next day. Transfection of the SSOs constructs and
siRNA was performed as in Subsection 2.2. The complexes were left in
the culture for 24 h, after which medium was removed, cells washed
with PBS 0.01M and fresh Dulbecco'sModiﬁed Eagle'smediumwithout
phenol red (to prevent interference with the method used to measure
the concentration of cholesterol) plus 10% LPDS (lipoprotein deﬁcient
serum) was added to the cultures to induce sterol starvation. Twenty-
four hours later, medium was removed and fresh Dulbecco's Modiﬁed
Eagle's medium without phenol red plus 10% LPDS supplemented
with 20 nmol per well of human LDL-C was added to the cells. Cells
were allowed to stay in the cholesterol-supplemented conditions for
12 h, after which cells were washed, and collected for RNA and protein
isolation.
2.4. Viability assay
Viability was assayed with the CellTiter-Glo Luminescent cell viabil-
ity assay (Promega) according to the manufacturer's protocol. Brieﬂy,
after 24 h incubation of the cells with the transfection complexes, the
cultures were allowed to equilibrate for 30 min at room temperature,
after which an equal volume of the CellTiter-Glo reagent was added to
the wells. Following cell lysis and luminescence stabilization, values of
luminescence were measured.
2.5. RNA expression analysis
Total RNAwas isolatedwith the RNeasy® plusmini kit (QIAGEN) ac-
cording to the manufacturer's protocol. In the animal experiment, total
RNA from livers was isolated with Tri-Reagent® (Sigma-Aldrich) and
DNase treated with RapidOut DNA Removal Kit (Thermo Scientiﬁc) ac-
cording to the manufacturer's protocols. Quantity and quality of the
total RNA were determined by NanoDrop by analysis of the ratios at
260/280 nm and 260/230 nm.
In the cell work RT-PCR was performed with 10 ng of the isolated
RNA in each reaction (total volume per reaction was 20 μL) with the
QIAGEN® OneStep RT-PCR kit (QIAGEN) and following the
manufacturer's protocol. In the animal experiments, RT-PCR was per-
formed with 25 ng of cDNA in each reaction (total volume per reaction
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following themanufacturer's protocol. All the primer sequences used, as
well as the PCR conditions, can be found in Supplementary Table A1.
The PCR products were analyzed in a 2% agarose gel in 1× TBE buffer
and visualized by SYBRsafe (Invitrogen, Molecular Probes) staining. Gel
imageswere captured by a Fluor-S gel documentation system (Bio-Rad)
with the Quantity One software (Bio-Rad).
2.6. Protein expression analysis
After treatments (SSOs transfection and depletion/addition of cho-
lesterol), cells were lysed in radio-immunoprecipitation assay (RIPA)
buffer (150 mmol/L NaCl, 1% Nonidet P40, 0.5% Deoxycholic acid, 0.1%
SDS, 50mmol/L Tris–HCl pH 8.0) supplemented with protease inhibitor
(cOmplete tablets, mini, EDTA-free, Roche), incubated for 20min at 4 °C
under agitation, centrifuged at 1000 rpm for 1min at 4 °C and the super-
natant transferred to a new tube. The total protein concentration was
determined with the BCA kit (Micro BCATM protein assay kit, Thermo
Scientiﬁc-Pierce Protein Research Products) according to the
manufacturer's instructions. Fixed amounts of total proteinwere loaded
in 8% Tris-glycine Novex® pre-cast gel (Life Technologies) and run for
3.5 h at 4 °C at 90 V (for PCSK9) or 1.5 h at 4 °C at 150 V (for LDLR).
After electrophoresis, the proteins were transferred to a membrane
using the iBlot system (Life Technologies), after which the membrane
was incubated in Odyssey blocking solution (Odyssey®) diluted 1:1 in
1× PBS, pH 7.4 (for PCSK9) or 5% dry milk powder in 20 mmol/L Tris
pH 7.5, 150 mmol/L NaCl, 0.1% Tween 20 (TBST) (for LDLR), for 1 h at
room temperature before incubation with the antibodies was per-
formed. Rabbit anti-PCSK9 polyclonal antibody (cat. no. 10007185, Cay-
man Chemical)was used at a dilution of 1:1,000, themonoclonalmouse
anti-ß-actin (cat. no. A5441, SIGMA) at a dilution of 1:10,000 and Rabbit
anti-LDLR (cat. n° LS-B8088-50, Nordic BioSite AB) at a dilution of
1:2500. Primary antibodieswere incubated overnight at 4 °C in Odyssey
blocking solution diluted 1:1 in 1× PBS, pH 7.4, 0.1% Tween20 (PBST) or
5%milk in TBST. Themembranewaswashedwith PBST or TBST, and in-
cubated with secondary antibodies (Goat anti-rabbit IRDye® 800CW,
cat. no. 926-32211, ODYSSEY® and Goat anti-mouse IRDye® 680LT,
cat. no. 926-68020, ODYSSEY®) both diluted at 1:20,000 in PBST or 5%
milk in TBST for 1 h at room temperature. After incubation, the mem-
brane waswashedwith PBST or TBST. The membrane was immediately
scanned using the Odyssey Classic equipment (LI-COR) and ﬂuores-
cence intensity of the secondary antibodies determined by the software
Image Studio 4.0.
Signals were plotted by μg-loaded protein and the slope of the
curves was calculated by method of least square. By this approach, the
slope of the curve describing the regression between the luminescence
signal and the amount of protein loaded reﬂects the concentration of
the protein of interest.
2.7. In vivo experiments
A fragment of the human PCSK9 genomic sequence including exon 7
to exon 9was PCR ampliﬁed and cloned into the plasmid pLIVE.Luc [35]
between theNheI and AgeI restriction sites, generating the reporter vec-
tor pLIVE.PCSK9.Luc (see Supplementary data, Fig. C1). Clones were iso-
lated by hygromycin B resistance and sequenced to assess insertTable 1
Oligonucleotides characteristics.
Antisense oligonucleotide Sequence
hP88 5′- GCA GAC AGC AUC AUG GCU-3′
hP872 5′- GAU GAC AUC UUU GGC AGA GAA-3′
hP1804 5′- CCG CUG GUC CUC AGG AAC-3′
hP1857 5′- CUG CCC CAU GGG UGC UGG-3′
CTR SSO 5′-CCU CUU ACC UCA GUU ACA-3′
Tm: melting temperature; nt: nucleotides; G: guanosine; C: cytosine; A: adenosine; U: uracyl;nucleotides order and orientation. Validation of the reporter vector
was made by co-transfection with SSO hP872 or control (CTR) SSO in
mouse hepatoma cell line Hepa1c1c7 (data not shown).
Female 20–22 gNMRI-micewere treatedwith a 2.0mL hydrodynam-
ic infusion to the liver through the tail vein, while anesthetized (n=15)
or left untreated (n=3) [36]. The infusion liquid consisted of a 0.9% NaCl
solution containing 5 μg reporter plasmid pLIVE.PCSK9.Luc together with
either 0.7 mg/kg SSO hP872 (n= 5), 3.7 mg/kg SSO hP872 (n= 5), or
3.7 mg/kg CTR SSO (n=5). The next day, livers were carefully harvested
post-mortem and snap frozen for subsequent total RNA isolation and
analysis. The animal experiments were approved by the Swedish Local
Board for Laboratory Animals. The experimentswere performed in accor-
dancewith the ethical permission anddesigned tominimize the suffering
and pain of the animals.
2.8. Data analysis
Data were expressed as mean ± SEM. Statistical analysis was per-
formed according to the guidelines published by Kusuoka and Hoffman
in 2002 [37]. Valueswere tested for normality by theD'Agostino–Pearson
normality test (omnibus K2). Statistical signiﬁcance was determined by
one-way ANOVA followed by a comparison of each treatment with the
group control by the Fisher's least signiﬁcant difference (LSD) test
(Graph Pad Prism 6 Software, Graph Pad Software, Inc.). In all cases
P b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Splice-switching oligonucleotides modulate splicing in human
hepatocyte cell lines
The compilation of the results obtained by the bioinformatics simu-
lations deﬁned four regions in the PCSK9 exon 8 and four SSOs were de-
signed to overlap those same regions (sequences, size and chemical and
physical characteristics can be found in Table 1).
After a preliminary screening at concentrations of 10, 25, 50, 100 and
200 nmol/L of SSOs in human hepatocyte cell line Huh7, it was deter-
mined that three SSOs (hP88, hP872 and hP8104) could induce the for-
mation of the splice variant (Fig. 1). The amplicons were sequenced
showing that the products obtainedwere the predict ones (Supplemen-
tary data, Figs. A1 and A2).
Of the tested SSOs, only hP872was effective at concentrations lower
than 50nmol/L (data not shown). To verify if the resultwas cell-speciﬁc,
transfections with the active SSOs were performed also in the HepG2
hepatocyte cell line. The expression of PCSK9 full-length (PCSK9ﬂ) and
PCSK9 splice variant (PCSK9sv) were quantiﬁed and normalized to
HPRT RNA. Fig. 2A and C show the PCSK9ﬂ mRNA expression, 24 h
after transfection with the different SSOs, in Huh7 and HepG2, respec-
tively. From these data, there is signiﬁcant reduction of the wild type
form in both cells lines for all treatments as compared to non-treated
cells (P b 0.05 and P ≤ 0.01). Regarding the formation of the PCSK9sv,
Fig. 2B and D, both cells lines show a statistically signiﬁcant difference
between hP872 treated and non-treated groups: at concentration of
50 nmol/L (Huh7 cells, a ratio between splice form and full length of
0.49 ± 0.054 and HepG2 cells, a ratio of 0.53 ± 0.12) and at concentra-
tion of 100 nmol/L (Huh7 cells, a ratio between splice form and fullTm (°C) Size (nt) Chemistry
68.9 18 2′- O-Me-PS fully modiﬁed
65.1 21 2′- O-Me-PS fully modiﬁed
72.8 18 2′- O-Me-PS fully modiﬁed
76.8 18 2′- O-Me-PS fully modiﬁed
40.1 18 2′- O-Me-PS fully modiﬁed
2′- O-Me-PS: 2′- O-methyl-phosphorothioate.
Fig. 1. SSOs promote exon 8 skipping in PCSK9 pre-mRNA inducing the splice form
PCSK9sv in a concentration-dependent way. RT-PCR of PCSK9 mRNA in Huh7 cells 24 h
post-transfection with SSOs at different concentrations. Fragments were analyzed in 2%
agarose gels and a representative gel from 3 independent experiments is shown. M indi-
cates the marker lane correspondent to 1Kb+ molecular marker.
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cells, all of the tested PCSK9 speciﬁc SSOs signiﬁcantly promote PCSK9sv
formation, with hP872 generating the most prominent effect. These re-
sults show that splice modulation is not cell line speciﬁc and that the
best performing SSO is hP872 at concentration of 100 nmol/L.Fig. 2.mRNA expression of PCSK9ﬂ and PCSK9sv in Huh7 and HepG2 cells after 24 h of treatme
Huh7; (B) PCSK9sv in Huh7; (C) PCSK9ﬂ in HepG2; (D) PCSK9sv in HepG2. Data represent the
calculated by one-way ANOVA test and comparison between treatment and control groups wa
*P b 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.3.2. Modulation of splicing in human hepatocyte cell lines does not affect
cell viability.
Viability of the cells upon SSO treatment for 24 h was measured to
identify potential toxic effects. Supplementary Fig. A3 shows the per-
centage of living cells for all the treatments in comparison with non-
treated cells. Based on the assay, no variation in viability was observed
for the Huh7 cell line. Regarding the HepG2 cell line, some variation in
viability was observed among the treatments, especially at higher con-
centrations (100 nmol/L). However, this seems to be transfection-
related and not an SSO-speciﬁc effect, since the same behavior is also
observed for the SSO control.
3.3. The modulation effect post-transfection is maintained after cholesterol
depletion and promotes increase in LDLR protein levels.
PCSK9 expression is known to be regulated by the levels of choles-
terol in themedium, increasingwith depletion and decreasing upon ad-
dition [14,38,39]. To conﬁrm that the splicemodulation can remain after
a period of cholesterol depletion/addition, cells were treated with the
SSO hP872 at 50 and 100 nmol/L for 24 h, after which, a period of cho-
lesterol depletion was induced for 24 h, followed by the addition of
20 nmol of cholesterol. In Fig. 3, the levels of total (A), full length
(B) and spliced (C) PCSK9 mRNA measured after this treatment (57 h
post-transfection) are presented. There is a statistically signiﬁcant dif-
ference (P b 0.0001) among all treatments, and a clear reduction of
the levels of the total and full-length mRNA can be observed when the
cells are treated with hP872 at 100 nmol/L (P=0.006 and P b 0.0001).nt with SSOs. Graphs represent the mRNA expression normalized to HPRT. (A) PCSK9ﬂ in
mean ± SEM obtained from duplicate wells of four independent experiments. A P-value
s determined post hoc by Fisher's LSD test. P b 0.05 was considered statistically signiﬁcant.
Fig. 3.mRNAexpression of PCSK9 total, full length (PCSK9ﬂ) and splice form (PCSK9sv) inHuh7 cells after treatmentwith SSOs followed by a period of depletion and addition of cholesterol.
Graphs represent the PCSK9mRNA expression 57 h post-transfection, and normalized to HPRT. Changes compared to non-treated cells (A) PCSK9 total, (B) PCSK9ﬂ and (C) PCSK9sv. Data
represent themean± SEMobtained from triplicatewells for three independent experiments. A P-value calculated by one-way ANOVA test and comparison between treatment and group
control was determined by post hoc Fisher's LSD test. P b 0.05 was considered statistically signiﬁcant. **P ≤ 0.01; **** P ≤ 0.0001.
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an increase in the PCSK9sv splice form, a decrease in the pro-protein
form is observed when the cells are treated with the SSOs. To verify
whether increased PCSK9sv levels induce the intended biological effect,
the levels of LDLR protein were analyzed (Fig. 5 and Supplementary
Fig. A4). As expected, an increase in LDLR levelswas observed, especially
when cells were treated with SSO hP872.
3.4. Splice-switching oligonucleotides modulate splicing in vivo when
co-transfected with a reporter vector
In order to assess the human sequence speciﬁc SSO in vivo, a liver
speciﬁc luciferase reporter vector containing the genomic sequence of
human PCSK9 including exon 7 to exon 9 was created, pLIVE.PCSK9.Luc
(Supplementary Fig. A5). Mice were co-injected with the reporter plas-
mid and the SSO hP872 or CTR SSO by hydrodynamic injection, a meth-
od known to result in preferential delivery to the liver and subsequentFig. 4. Protein analysis of PCSK9 pro-protein (B), splice variant (C) and full length (D) in S
A) Representative western blot of PCSK9 and actin. Left panel: Huh7 cells untreated, siRNA tr
50 nmol/L or 100 nmol/L. B-D) Quantiﬁcation of protein from the different splice forms pro-pr
ratio from the PCSK9 bands by the respective beta-actin loading control. Values expressed asm
one-way ANOVA test and comparison between treatment and group control was determined
***P ≤ 0.001; ****P ≤ 0.0001.high expression [40,41] of the reporter plasmid. The expression of the
vector was veriﬁed by luciferase mRNA.
Results regarding the mRNA expression obtained from the livers har-
vested one day after co-injection are presented in Fig. 6 (and also Supple-
mentary Figs. A6, A7 and A8). Comparable expression of the reporter
system was found in all the mice groups, see Fig. 6A, where the total
amount (calculated as full length plus splice form) of PCSK9_E7-9 is
represented, indicating an even distribution of the reporter plasmid in
the livers. As for the formation of the splice variant, data show that a com-
plete conversion to the splice form (PCSK9_E7-9Δ8) is obtainedwhen SSO
hP872 is present (Fig. 6B). The effect is also concentration dependent.4. Discussion
For several years, SSOs have been used to modulate alternative
splicing, especially in cases where mutations interfere with the normalSO treated Huh7 cells followed by a period of starvation and feeding with cholesterol.
eated and CTR SSO treated. Right panel: Huh7 cells untreated and treated with hP872 at
otein (B), splice variant (C) and full-length (D). Graphs represent the intensity derivatives
ean± SEM from triplicate blots in three independent experiments. A P-value calculated by
by post hoc Fisher's LSD test. P b 0.05 was considered statistically signiﬁcant. **P ≤ 0.01;
Fig. 5. Protein analysis of LDLR in SSO treatedHuh7 cells followed by a period of starvation
and feeding with cholesterol. Quantiﬁcation of LDLR protein in a representative experi-
ment. Graph represents the intensity derivatives from the LDLR bands. Values expressed
as mean ± SEM from triplicate blots. A P-value calculated by one-way ANOVA test and
comparison between treatment and group control was determined by post hoc Fisher's
LSD test. P b 0.05 was considered statistically signiﬁcant. *P b 0.05.
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the resulting production of aberrant transcript forms [42].
For theﬁrst time,we describe a conceptwhere the splicemodulation
selectively induces a natural intracellular protein that becomes retained
in the cell. The effect, after only a single treatment, is maintained even
after a period of stimulation of the mRNA expression by cholesterol de-
pletion/addition and persists with a duration that approaches the half-
life of the compound (Figs. 3, 4 and 5).
The 2′-O-methyl-phosphorothioate chemistry used in this study is
one of the oldest and best characterized in the ﬁeld of oligonucleotides
-mediated gene therapy in terms of speciﬁcity, efﬁciency, toxicity and
bio-distribution and is currently being employed in clinical trials [43].
One major characteristic of oligonucleotides with this chemistry (as
for many other SSOs chemistries) is their preferential accumulation in
the liver and kidney [44], making them excellent therapeutics for
liver-related diseases. This tissue speciﬁcity is very important, since it
prevents side effects by interfering in other tissue functions, something
that cannot be achieved upon systemic delivery of other therapeutic
drugs such as antibodies.Fig. 6.mRNA expression of PCSK9_E7-9 total (full length + splice form), and splice form (PCSK
vector pLIVE.PCSK9.Luc. Graphs represent the PCSK9_E7-9 total (A) and PCSK9_E7-9Δ8 (B)
mean ± SEM obtained from n=3 (untreated mice, CTR SSO and hP872 0.7 mg/kg) and n=5
between treatment and group control was determined by post hoc Fisher's LSD test. P b 0.05 wIn 2011, Medina et al. [30] demonstrated in HepG2 cells and African
Green monkeys that the addition of cholesterol after a period of sterol
depletion increases the full-length isoform of PCSK9, while it decreases
the splice variant. Our data show that when cells are treated with the
speciﬁc SSOs, the splice variant does not decrease as quickly as the
full-length form, as previously reported [30]. Additionally, the amount
of the splice variant is signiﬁcantly higher when compared with non-
treated cells, further proving the efﬁciency of this strategy.
Thismethod is independent of the cell line used andnon-toxic under
the tested conditions. Furthermore, preliminary experiments in murine
hepatoma Hepa1c1c7 cell line done in our laboratory with mouse se-
quences and targeting the same and other regions did not show any sig-
niﬁcant effect in the formation of the splice form (data not shown),
indicating that this mechanism is human-speciﬁc.
PCSK9 inhibition through antibody-mediated sequestration is a
highly active therapeutic ﬁeld with many clinical trials ongoing. In the
main, these treatments seem efﬁcacious and well tolerated, although
long-term safety has not yet been established. Moreover, this procedure
is non-organ selective and does not take into account the potential non-
liver-related functions of PCSK9 [45]. Current means to instead inhibit
PCSK9 expression focus on the down-regulation of gene expression by
siRNA or antisense oligonucleotides that promote RNase H activity. Re-
cently, the potent CRISPR-associated systemhas also been tried [27], but
issues regarding immunity induction towards the transport vehicle, the
division rate among cells in the target tissue and concerns about possi-
ble off-target mutagenesis have to be considered.
Our approach, which changes the isoform pattern, by interfering
with RNA splicing, is a novel and possibly safer way of interfering with
the gene expression. It can be considered highly physiological since no
aberrant mRNA or protein is induced, while only the balance between
splice forms is changed. This is also important if we take in account
that other biological functions for PCSK9 may exist outside the liver.
While 2′-O-methyl chemistry has come of age, there are many
other synthetic nucleotides, which show excellent activity. Thus,
we recently demonstrated that both locked nucleic acid (LNA) and
phosphorodiamidate morpholino (PMO) oligomers correct defects
in an X-linked agammaglobulinemia model [46]. Since LNA is also
readily taken up in the liver, the same advantage in selectivity
would apply [47]. Moreover, PMOs conjugated to peptides showing
cell-penetrating activity were very active in vivo. Thus, while our ap-
proach for PCSK9 demonstrates proof of concept, there are many
possibilities for further improvements. It is not until splice switching9_E7-9Δ8) in livers from mice after treatment by co-injection of SSO hP872 and reporter
mRNA expression 24 h after co-injection, and normalized to Luc. Data represent the
(hP872 3.7 mg/kg) animals. A P-value calculated by one-way ANOVA test and comparison
as considered statistically signiﬁcant. ** P ≤ 0.01.
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hepatocytes and/or mice with humanized livers, that the full poten-
tial of this technology will be revealed.
Another important parameter is that manufacturing costs for thera-
peutic and synthetic oligonucleotides have decreased over time. Apart
from tissue availability, pharmacokinetics is crucial. Many therapeutic
oligonucleotides can be dosed only once a month, with maintained ac-
tivity, which is highly attractive [24,43]. It may also be that combination
therapies using e.g. antibodies togetherwith oligonucleotideswill result
in enhanced treatment effects.
5. Conclusion
In summary, PCSK9 activity can be modulated by splice-switching
oligonucleotides through the induction of a unique intracellular
retention form, being shown at both mRNA and protein levels. Thus,
we believe that we have been able to demonstrate that altering the
ratio of naturally occurring splice variants of PCSK9 is a viable approach
for interfering with cholesterol metabolism. Further developments are
needed to bring this strategy into the clinic.
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